Portage Biotech Files 6-K, Confirms Foreign Private Issuer Status

Ticker: ATON · Form: 6-K · Filed: Feb 28, 2024 · CIK: 1095435

Portage Biotech INC. 6-K Filing Summary
FieldDetail
CompanyPortage Biotech INC. (ATON)
Form Type6-K
Filed DateFeb 28, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, foreign-issuer

TL;DR

**Portage Biotech just filed a standard 6-K, confirming its foreign private issuer status and BVI address.**

AI Summary

Portage Biotech Inc. filed a Form 6-K with the SEC on February 28, 2024, for the month of February 2024, indicating its status as a foreign private issuer. The filing confirms the company's business address as Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110. This report, with Commission File Number 001-40086, will be incorporated by reference into future filings.

Why It Matters

This routine filing confirms Portage Biotech's compliance with SEC reporting requirements as a foreign private issuer, providing transparency to investors regarding its operational status and location.

Risk Assessment

Risk Level: low — This is a routine administrative filing and does not indicate any specific financial or operational risks.

Key Players & Entities

FAQ

What type of report did Portage Biotech Inc. file?

Portage Biotech Inc. filed a Form 6-K, which is a report of a foreign private issuer.

When was this 6-K report filed?

The 6-K report was filed on February 28, 2024, for the month of February 2024.

What is the Commission File Number for Portage Biotech Inc.?

The Commission File Number for Portage Biotech Inc. is 001-40086.

Where are the principal executive offices of Portage Biotech Inc. located?

The principal executive offices of Portage Biotech Inc. are located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110.

Will this 6-K report be incorporated by reference?

Yes, the report on Form 6-K (including exhibits) shall be deemed to be incorporated by reference into future filings.

Filing Stats: 325 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2024-02-28 17:17:22

Filing Documents

Management's Discussion and Analysis for the three and nine months ended December 31, 2023

Management's Discussion and Analysis for the three and nine months ended December 31, 2023. 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: February 28, 2024 PORTAGE BIOTECH INC. By: /s/ Allan Shaw Allan Shaw Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing